# Market Catalyst Impact Brief

As of: 2026-05-13
Scope: open catalysts starting within 45 days; stale after 14 days.

Boundary: Offline deterministic research brief from supplied dataset only. No live data, broker connectivity, predictions, investment advice, or trade recommendations.

| Metric | Value |
| --- | ---: |
| Records | 3 |
| High urgency | 1 |
| Stale review | 1 |
| Over budget | 2 |
| Missing risk context | 0 |
| Aggregate portfolio weight | 33.35% |
| Aggregate weighted attention | 23.40% |

| Attention | Ticker | Window | Event | Impact | Flags | Base Case |
| ---: | --- | --- | --- | --- | --- | --- |
| 100 | PFE | 2026-05-20..2026-05-24 | regulatory decision | mixed thesis context | stale_review, over_budget, broker_context | Decision is mostly expected but clarifies launch timing. |
| 89 | SPY | 2026-06-17 | macro release | mixed thesis context | missing_evidence_freshness, over_budget | Statement broadly matches market-implied policy path. |
| 84 | NVDA | 2026-06-02 | product launch | positive thesis context | broker_context | Product roadmap details support existing accelerator growth expectations. |

## PFE - Pfizer Inc.

- Catalyst id: demo-pfe-fda-2026
- Event: regulatory decision (2026-05-20..2026-05-24); status: watching
- Attention score: 100; catalyst score: 87; urgency: high; review: stale
- Impact label: mixed thesis context; thesis impact: mixed; confidence: 0.68
- Exposure context: weight 3.10%; weighted attention 1.83%; risk budget 25,000.00; max loss 32,000.00
- Evidence state: stale; source ref: FDA calendar and PFE pipeline note
- Required review action: verify_source
- Bull: Approval expands pipeline credibility and supports forward revenue mix.
- Base: Decision is mostly expected but clarifies launch timing.
- Bear: Delay or restrictive label pressures near-term sentiment.
- Evidence URLs: https://example.com/fda-calendar, https://example.com/pfe-pipeline-update

## SPY - S&P 500 ETF Trust

- Catalyst id: demo-fomc-june-2026
- Event: macro release (2026-06-17); status: confirmed
- Attention score: 89; catalyst score: 83; urgency: medium; review: current
- Impact label: mixed thesis context; thesis impact: mixed; confidence: 0.9
- Exposure context: weight 22.00%; weighted attention 16.43%; risk budget 75,000.00; max loss 90,000.00
- Evidence state: missing; source ref: FOMC public calendar
- Required review action: monitor_date
- Bull: Policy language indicates lower real-rate pressure for duration assets.
- Base: Statement broadly matches market-implied policy path.
- Bear: Inflation language reprices yields higher and weighs on multiples.
- Evidence URLs: https://example.com/fomc-calendar

## NVDA - NVIDIA Corporation

- Catalyst id: demo-nvda-computex-2026
- Event: product launch (2026-06-02); status: scheduled
- Attention score: 84; catalyst score: 84; urgency: medium; review: current
- Impact label: positive thesis context; thesis impact: positive; confidence: 0.74
- Exposure context: weight 8.25%; weighted attention 5.13%; risk budget 60,000.00; max loss 52,000.00
- Evidence state: fresh; source ref: NVDA Computex keynote tracker
- Required review action: monitor_date
- Bull: Management confirms accelerated platform demand and shorter supply constraints.
- Base: Product roadmap details support existing accelerator growth expectations.
- Bear: Launch focuses on refresh timing without incremental demand signals.
- Evidence URLs: https://example.com/nvidia-computex-keynote, https://example.com/channel-check-gpu-supply
